Carrick NewsroomPress Releases

Saama Expands Leadership Team With Addition Of Visionary Medical Affairs Expert Kenneth L. Massey, Pharm.D.

CAMPBELL, CA (April 02, 2018)— Saama Technologies, Inc., a leading clinical data analytics company, today announced that Kenneth L. Massey, Pharm.D., one of the foremost medical affairs professionals in the life sciences industry, has joined the company in the key position of Chief Life Sciences Officer. Ken brings 30 years of medical affairs and drug development experience at leading global pharmaceutical companies to his new role at Saama.

As Chief Life Sciences Officer, Ken will be responsible for driving market leadership for Saama’s award-winning life sciences data analytics solutions. Ken will oversee pre-Phase 1 through Phase 3-plus clinical development, identifying and activating opportunities for emerging and existing clients to leverage Saama’s Clinical Analytics Platform to successfully launch critical new therapies into the marketplace.

“Saama truly believes that data and analytics will play a critical role in transforming the overall life sciences industry to the benefit of humanity, and we are confident that Ken will help Saama lead this revolution,” said Suresh Katta, Founder and CEO of Saama Technologies. “Ken’s decades of strategic medical affairs expertise and clinical experience will further enhance our platform’s ability to leverage Artificial Intelligence and Deep Learning to enable life sciences companies to optimize the cycle time, cost, and outcomes of their critical clinical development business processes.”

“Saama’s positive disruption of the life sciences industry is extremely impressive and signals a new era in clinical development opportunities,” said Ken. “I am excited to apply my pharmaceutical, clinical, and academic acumen to enhancing Saama’s growth, distinguishing its unique platform and suite of products, and expanding its leadership position in today’s dynamic healthcare environment.”

Ken joins Saama from Merck & Company, where he served as Vice President, Medical Affairs for the past five years. At Merck, Ken was responsible for all aspects of strategic planning, governance and management of the U.S. Medical Affairs organization. Ken’s extensive experience creating, developing and leading medical affairs organizations at any point along the organizational continuum and across a full range of therapeutic areas was additionally demonstrated during prior tenures at Novartis and Mitsubishi Tanabe Pharma America, where he spent a combined total of 13 years.

Ken has received numerous awards and honors, including the inaugural Novartis CEO’s Diversity and Inclusion Award, which recognizes individuals and teams committed to integrating diversity and inclusion principles with business practices. Ken is widely published in leading industry and professional society journals on a range of clinical, pharmacological and therapeutic topics. Ken received both his Bachelor of Science in Pharmacy and his Doctor of Pharmacy from the University of Florida Gainesville College of Pharmacy.

About Saama

Saama Technologies is the advanced data and analytics company delivering actionable business insights for life sciences and the Global 2000. Saama is singularly focused on driving fast, flexible, impactful business outcomes for its clients through advanced data and analytics. Saama’s unique “hybrid” approach integrates focused solutions and expertise across the life sciences domain, business consulting, machine learning, automated data management, cloud and big data technologies. Saama’s approach integrates manual and disconnected data initiatives into a well-aligned roadmap facilitating the client’s journey from strategy through solution implementation to generate business

About Carrick Capital Partners
Who We Are
A firm of enterprise software, SaaS, and technology enabled services investors and operating executives with substantial experience founding, scaling, and optimizing market leading businesses.
Our Approach
We work with management to identify and improve critical areas of their business - focusing on the priorities that align with our experiences and that will deliver the highest strategic impact in both the short-term and long-run.
Why We Are Different
We have a concentrated number of companies in our portfolio so that we can build substantial relationships with each management team and ensure our firm's commitment to each company's goals.
Latest News
Complia Logo.jpg
Complia Health and the Interim HealthCare franchise network continue a close, longstanding partnership and have extended a many-year agreement following a decade of proven success.
March 5, 2020
Accolade Logo.jpg
Seattle, WA (February 28, 2020) – Accolade, Inc. (“Accolade”), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, today announced it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Accolade intends to list its common stock on the Nasdaq Global Select Market under the ticker symbol ACCD.
February 28, 2020
Saviynt Logo.jpg
Saviynt Announces the Return of Converge EMEA Conference on March 11th, 2020, Featuring Keynote Speaker Dex Torricke-Barton
February 16, 2020